This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2000;283:1679.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has asked health care professionals to caution patients about the risk of potentially significant interaction between St John's wort (Hypericum perforatum), an herbal product marketed as a dietary supplement, and other drugs, including indinavir, a protease inhibitor (PI) used for HIV infection.

The agency's warning is based on a study conducted by the National Institutes of Health with eight healthy, HIV-negative volunteers. Participants received 800 mg of indinavir administered on an empty stomach every 8 hours for 4 doses, with serial pharmacokinetic sampling before and after the fourth dose. For the next 14 days, volunteers took 300 mg of St John's wort (0.3% hypericin) three times daily with food. On the last day of St John's wort, volunteers again received took 800 mg of indinavir every four hours for a total of 4 doses, with pharmacokinetic sampling before and for 5 hours serially after the fourth . . . [Full Text of this Article]